Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: TRI, FDA

Kintor Pharmaceutical Announced FDA Has Greenlighted Pyrilutamide's Phase II Clinical Trial for Androgenetic Alopecia in the US


SUZHOU, China, July 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has greenlighted pyrilutamide's phase II clinical trial for androgenetic alopecia(AGA) to be conducted in the US.

The phase II trial is a randomized, double-blind, vehicle-controlled, parallel group study,  designed to evaluate the efficacy and safety of pyrilutamide in male subjects with AGA. The primary endpoint for the trial is the change from baseline in non-vellus TAHC (Target Area Hair Counts) at Week 24 in comparison to vehicle.

Dr. Tong Youzhi, the founder, chairman, and CEO of Kintor Pharmaceutical, commented, "We are delighted to receive the clearance from the US FDA for this phase II clinical trial of pyrilutamide in AGA Subjects. This has been the fifth clinical study sponsored by Kintor in the US. The phase II clinical trial of pyrilutamide for the treatment of AGA in China is close to end, and we expect the data read-out in this quarter. We have adopted the strategy of conducting clinical trials both in China and the US , and wish pyrilutamide would benefit people suffering from AGA in China and global."

About Pyrilutamide (KX-826)

Pyrilutamide, a topical AR antagonist with a specific target, can inhibit the combination of androgen receptor and androgen in hair follicle sebaceous glands, thereby treating androgenetic alopecia and acne.

About Kintor Pharmaceutical Limited

Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancer, alopecia and acne. For more information, visit www.kintor.com.cn.

SOURCE Kintor Pharmaceuticals


These press releases may also interest you

at 05:35
The "Mining In Central Africa 2021" report has been added to ResearchAndMarkets.com's offering. Central Africa is a significant producer of the world's cobalt, tantalum, manganese, diamonds and copper. The region's mining industry is benefiting from...

at 05:30
The "Biogas Market 2021-2028" report has been added to ResearchAndMarkets.com's offering. The global biogas market size is expected to reach USD 81.37 billion by 2028 and is expected to expand at a CAGR of 4.4% from 2021 to 2028. Electricity was the...

at 05:30
The self-inflating bag market size is set to grow by USD 71.79 mn from 2020 to 2024, at a CAGR of 5% according to the latest market report by Technavio. ...

at 05:30
The "Bangladesh Buy Now Pay Later 2021" report has been added to ResearchAndMarkets.com's offering. According to the Q2 2021 BNPL Survey, BNPL payment in the country is expected to grow by 71.5% on annual basis to reach US$ 222.4 million in 2021....

at 05:25
The "India Outbound Tourism Market on the Rise Post the COVID-19 Pandemic and Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. India's outbound tourism market is set to surpass US$ 40 billion by 2026 with an impressive...

at 05:05
The global data center substation market size is expected to reach USD 14.80 billion by 2030, registering a CAGR of 5.6% from 2021 to 2030, according to a study conducted by Grand View Research, Inc. Data centers are a vital part of the IT...



News published on 11 july 2021 at 09:03 and distributed by: